EVALUATE CDK4/6 INHIBITOR PD0332991 ALONE/WITH RADIATION IN DIPG MOUSE MODEL

在 DIPG 小鼠模型中单独/使用辐射评估 CDK4/6 抑制剂 PD0332991

• 批准号: 8363197
• 负责人: Oren Josh Becher
• 金额: $ 0.31万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363197
• 关键词: Blood - brain barrier anatomy; CDK4 gene; Data; Funding; Future; Grant; Image; Institution; Microscopy; Modeling; Mus; National Center for Research Resources; Platelet-Derived Growth Factor; Principal Investigator; Radiation; Radiation therapy; Research; Research Infrastructure; Resources; Signal Transduction; Source; United States National Institutes of Health; Weight; Work; cost; in vivo; inhibitor/antagonist; interest; mouse model; neoplastic cell; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Aim 1. To evaluate whether treatment with PD0332991 will prolong the survival of mice harboring DIPG driven by PDGF signaling and loss of Ink4a-ARF Aim 2. To investigate whether in vivo synchronization of DIPG tumors cells with PD0332991 can increase the efficacy of radiation therapy When working with this model in a previous institution, I have only used T2 weighted imaging to image the tumor-bearing mice prior to treatment. However, it would be useful to carry out T1+contrast studies as we are also interested in studying the blood-brain-barrier (BBB) and in the future will be generating tumor-bearing mice with impaired BBB. I would suggest that we do T1+contrast studies on a couple of select mice with a nice size tumor on T2. Ultimately, data from this project will be used for an R01 submission at the end of this year.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 目的1。评估PD0332991的治疗是否会延长由PDGF信号驱动和INK4A-ARF损失驱动的DIPG的生存率 目的2。研究与PD0332991的DIPG肿瘤细胞的体内同步是否可以提高放射治疗的疗效 在上一个机构中使用该模型时，我仅使用T2加权成像来对肿瘤的小鼠进行治疗。 但是，进行T1+对比度研究将很有用，因为我们也有兴趣研究血脑屏障（BBB），并且将来将产生患有BBB受损的肿瘤小鼠。 我建议我们对T2上有很好尺寸肿瘤的几只精选小鼠进行T1+对比研究。 最终，该项目的数据将在今年年底用于R01提交。